Pharmafile Logo

News and Press Releases

ESCMID Global 2025: Shionogi presents real-world data demonstrating better clinical outcomes when Fetcroja / Fetroja (cefiderocol) is used as empiric or documented therapy as compared to salvage therapy for the treatment of Gram-negative bacterial infections

Data from five European countries demonstrates the effectiveness of cefiderocol against Gram-negative pathogens considered as high or critical priorities by the WHO, including high rates of clinical cure and day...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 8, 2025

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

19 December 2024 – Tokyo, Japan and Cambridge, UK, – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares –...

Category: Drug Delivery, Drug Discovery
Posted: December 19, 2024

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio...

Category: BioManufacturing
Posted: November 6, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Inceptua Group Expands Early Access Programme to Latin America

15 May 2024 -- Luxembourg -- Inceptua, a global pharmaceutical service company, announces an expansion of an Early Access Programme for cefiderocol for eligible patients in Argentina, Chile, Colombia, Guatemala,...

Category: Clinical Trials, Drug Delivery, Logistics
Posted: May 15, 2024

Inceptua
Info@inceptua.com
2 place de Paris 2314 Luxembourg

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

9 May 2024 -- Tokyo, Japan and Cambridge, UK -- Nxera Pharma provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March...

Category: Drug Discovery, Other
Posted: May 9, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Positive Results from Phase 3 Clinical Trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan

26 February 2024 -- Osaka, Japan -- Shionogi & Co announces the submission of a marketing approval application for the digital therapeutic app SDT-001, for commercialisation and sale in Japan,...

Category: Clinical Trials
Posted: February 27, 2024

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...

Category: Clinical Trials
Posted: September 20, 2023

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK